- Hung M-C, Lau Y-K. Basic science of HER-2/neu: a review. Semin Oncol 1999; 4 (Suppl 12): 51-9.
- King CR, Kraus MH, Aaronsen SA. Amplification of a novel c-erbBrelated gene in a human mammary carcinoma. Science 1985; 229: 974-6.
- Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogens 1990; 5: 953-62.
- Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
- Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinational ligandreceptor interactions. FEBS Lett 1997; 410: 83-6.
- Hynes NE, Gerber HA, Saurer S, Groner B. Overexpression of the cerbB-2 protein in human breast tumor cell lines. J Cell Biochem 1989; 39: 167-73.
- Bargmann CL, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-30.
- Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82.
- van de Vijver MJ, Peterse JL, Mod WJ, et al Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in stage II breast cancer. New Engl J Med 1988; 319: 1239-45.
- Gusterson BA, Gelber RD, Goldhirsch KN, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
- Norton L, Slamon D, Leyland-Jones B, et al Overall survival (OS) advantage to herceptin (H) in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 127a (Abstr 283).
- Menard S, Casalina P, Tomasic G, et al. Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviours. Breast Cancer Res Treat 1999; 55: 169-77.
- Thor AD, Berry DA, Budman DR, et al. erbB-2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer lnst 1998; 90: 1361-70.
- Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, nodepositive breast cancer. J Clin Oncol 1999; 18: 3471-9.
- Lipton A AIi SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 71 a (Abstr 274).
- Leitzel K, Teramoto Y, Konrad K, et al Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-35.
- Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1998; 2: 387-94.
- Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-4.
- Baselga J, Norton L, Albanell J, et al. Recombinant humanized antiHER2 antibody (Herceptin) enhances the antitumcr activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
- Mass RD, Sanders C, Charlene K, et al The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000; 19: 75a (Abstr 291).
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research